Exelixis Wins Patent Appeal Against MSN, Reinforcing Cabometyx Exclusivity

What happened

Exelixis announced that the U.S. Court of Appeals for the Federal Circuit affirmed a key portion of the 2024 district court judgment in its favor, upholding the validity of three patents covering cabozantinib against MSN Laboratories' challenge. This appellate win bolsters the intellectual property estate around CABOMETYX, which faces composition-of-matter expiry in 2026 but has secondary patents extending to 2030–2033. The decision reduces the near-term risk of generic entry from MSN, though other ANDA filers and ongoing litigations remain active Paragraph IV threats. The master report had already identified the patent cliff as a key structural risk, and this news removes one specific uncertainty without eliminating the broader threat landscape. Investor reaction may be muted given the stock's recent run and already crowded positioning, as the market had partly priced in a favorable outcome.

Implication

Investors should view the patent affirmation as a positive but not transformative event: it reduces one specific litigation overhang but leaves the broader patent cliff and pricing pressures intact. The master report's base case already assumed Cabometyx would maintain exclusivity until secondary patents expire, so the news largely confirms that assumption rather than creating new upside. At ~$44 with a P/E of 17x and limited margin of safety, the stock remains fairly valued; the win does not justify adding at current levels unless other catalysts (e.g., zanzalintinib progress, above-guidance Cabometyx) materialize. A pullback toward the attractive entry of $38 would offer a better risk-adjusted opportunity, while a break above $52 would signal overvaluation. Monitoring for further ANDA challenges and FDA decisions on zanzalintinib remains critical, as those are larger value drivers than this legal update.

Thesis delta

The appellate affirmation mildly de-risks the intellectual property portion of the thesis, supporting the assumption that Cabometyx retains exclusivity beyond 2026 via secondary patents. However, it does not alter the core concerns around single-product concentration, pricing pressure, and the unproven zanzalintinib franchise. The overall WAIT rating and entry point of $38 remain appropriate.